Hansa Biopharma AB (publ) (STO:HNSA)
Sweden
· Delayed Price · Currency is SEK 27.08
+1.06 (4.07%)
Apr 28, 2026, 5:29 PM CET
Hansa Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 190.49 | 222.27 | 171.32 | 134.09 | 154.53 | 33.88 | Upgrade
|
| Revenue Growth (YoY) | 4.84% | 29.74% | 27.76% | -13.22% | 356.12% | 455.56% | Upgrade
|
| Cost of Revenue | 76.83 | 83.56 | 83.55 | 63.14 | 38.48 | 15.43 | Upgrade
|
| Gross Profit | 113.66 | 138.71 | 87.76 | 70.95 | 116.05 | 18.45 | Upgrade
|
| Selling, General & Admin | 386.12 | 356.55 | 344.27 | 450.49 | 337.86 | 327.27 | Upgrade
|
| Research & Development | 297.81 | 304.74 | 375.72 | 411.33 | 346.24 | 230.76 | Upgrade
|
| Other Operating Expenses | - | - | - | 0.29 | 8.06 | - | Upgrade
|
| Operating Expenses | 683.93 | 661.28 | 719.99 | 862.11 | 692.17 | 558.03 | Upgrade
|
| Operating Income | -570.27 | -522.58 | -632.22 | -791.16 | -576.12 | -539.58 | Upgrade
|
| Interest Expense | -223.4 | -122.49 | -134.08 | -105.52 | -43.67 | -0.69 | Upgrade
|
| Interest & Investment Income | - | 7.33 | 20.83 | 28.06 | 8.83 | 0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | 163.92 | 165.34 | -71.39 | 37.81 | 5.95 | -7.4 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 12.65 | - | -4.97 | -0.53 | Upgrade
|
| EBT Excluding Unusual Items | -629.75 | -472.4 | -804.21 | -830.81 | -609.98 | -548.13 | Upgrade
|
| Merger & Restructuring Charges | -59.45 | -59.45 | - | - | - | - | Upgrade
|
| Pretax Income | -689.2 | -531.84 | -804.21 | -830.81 | -609.98 | -548.13 | Upgrade
|
| Income Tax Expense | 2.38 | 2.27 | 3.03 | 0.91 | 1.16 | 0.15 | Upgrade
|
| Net Income | -691.58 | -534.11 | -807.24 | -831.72 | -611.13 | -548.28 | Upgrade
|
| Net Income to Common | -691.58 | -534.11 | -807.24 | -831.72 | -611.13 | -548.28 | Upgrade
|
| Shares Outstanding (Basic) | 90 | 81 | 63 | 53 | 45 | 44 | Upgrade
|
| Shares Outstanding (Diluted) | 90 | 81 | 63 | 53 | 45 | 44 | Upgrade
|
| Shares Change (YoY) | 34.63% | 29.23% | 19.59% | 16.95% | 1.01% | 5.45% | Upgrade
|
| EPS (Basic) | -7.71 | -6.58 | -12.85 | -15.83 | -13.60 | -12.33 | Upgrade
|
| EPS (Diluted) | -7.71 | -6.58 | -12.85 | -15.83 | -13.60 | -12.33 | Upgrade
|
| Free Cash Flow | -554.28 | -549.17 | -675 | -755.94 | -506.06 | -483.57 | Upgrade
|
| Free Cash Flow Per Share | -6.18 | -6.76 | -10.74 | -14.39 | -11.27 | -10.87 | Upgrade
|
| Gross Margin | 59.67% | 62.41% | 51.23% | 52.91% | 75.10% | 54.47% | Upgrade
|
| Operating Margin | -299.37% | -235.11% | -369.04% | -590.00% | -372.83% | -1592.71% | Upgrade
|
| Profit Margin | -363.06% | -240.30% | -471.20% | -620.25% | -395.49% | -1618.40% | Upgrade
|
| Free Cash Flow Margin | -290.98% | -247.08% | -394.01% | -563.74% | -327.50% | -1427.38% | Upgrade
|
| EBITDA | -567.78 | -520.07 | -629.67 | -788.33 | -573.71 | -538.06 | Upgrade
|
| EBITDA Margin | -298.07% | -233.99% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 2.49 | 2.5 | 2.55 | 2.83 | 2.41 | 1.52 | Upgrade
|
| EBIT | -570.27 | -522.58 | -632.22 | -791.16 | -576.12 | -539.58 | Upgrade
|
| EBIT Margin | -299.37% | -235.11% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.